Rosiglitazone is a PPAR-γ-dependent transcriptional activator of Ucp2 (Medvedev et al., 2001; Chen et al., 2006), and increases retinal Ucp2 expression (Figure 7), but does not seem to promote Ucp2 mediated neuroprotection in the microbead model of glaucoma. This evidence concerns the gene PPARG and glaucoma.